3rd Quarter - Report

VIATRIS INC. for VIATRIS INC

Firm
Client
Income
—
Expenses
$230,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Federal policy regarding Public Law 113-54, the Drug Quality and Security Act; FDA proposed rule, Supplemental Applications Proposing Labeling Changes For Approved Drugs And Biological Products, Docket Number FDA-2013-N-0500, provisions relating to generic drug labeling changes; Proposed FDA rule, "Electronic Distribution of Prescribing Information for Human Prescription Drugs Including Biological Products," RIN: 0910-AG18, provisions relating to the use of electronic package inserts for human pharmaceuticals and biologics; Implementation of Biosimilars in the Affordable Care Act (ACA), Biosimilar Naming, Implementation of FDASIA and Generic Drug User Fee Act; The Generic Drug Pricing Transparency Act, H.R. 4437; Risk Evaluation Mitigation Strategies, Potential legislation relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing; The Fair Access for Safe and Timely (FAST) Generics Act. PEPFAR program supply chain management

LobbyistCovered position, as disclosed
NIMISH SHAH —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); White House Office

Bills named: H.R. 4437 (113th)

Trade (domestic/foreign) TRD

General trade issues, TPP

LobbyistCovered position, as disclosed
NIMISH SHAH —

Contacted: SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; White House Office

Copyright/Patent/Trademark CPT

Patent Settlements, Patent Reform

LobbyistCovered position, as disclosed
NIMISH SHAH —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA); White House Office

Taxation/Internal Revenue Code TAX

Tax Reform, Tax Extenders, Corporate tax; Administrations Tax Reform and 2015 Budget Proposals; Senate and House Committee Tax Reform Proposals; Proposals to reform domestic and international tax structures

LobbyistCovered position, as disclosed
NIMISH SHAH —

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE; White House Office

Budget/Appropriations BUD

Global Health Appropriations, President's Emergency Plan for AIDS Relief funding, Global Fund funding, FY 2015 Budget, FY2015 House and Senate Appropriations, Funding for FDA, Funding for the Office of Generic Drugs, Generic Drug User Fees

LobbyistCovered position, as disclosed
NIMISH SHAH —

Contacted: SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; White House Office

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.